Fresenius Group Overview

Outlook

Group Outlook 2020

In 2020, we expect to increase Group sales1 by 4% to 7% in constant currency. We project Group net income2,3 to increase by 1% to 5% in constant currency.

  Targets 20204 Fiscal year 20195
Fresenius Group
Sales growth (in constant currency) 4% – 7% € 35,409 million
Net income2 growth
(in constant currency)		 1% – 5% € 1,879 million
Fresenius Medical Care
Sales growth (in constant currency) Mid-to-high
single-digit
%-range		 € 17,477 million
Net income6 growth (in constant currency) Mid-to-high
single-digit
%-range		 € 1,236 million
Fresenius Kabi
Sales growth (organic) 3% – 6% € 6,919 million
EBIT growth (in constant currency) -4% – 0% € 1,205 million
Fresenius Helios
Sales growth (organic) 3% – 6% € 9,234 million
EBIT growth 3% – 7% € 1,025 million
Fresenius Vamed
Sales growth (organic) 4% – 7% € 2,206 million
EBIT growth 5% – 9% € 134 million

 

  • 1 Base 2019: € 35,409 million, including IFRS 16, including NxStage operations
  • 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
  • 3 Base 2019: € 1,879 million, before special items, including IFRS 16, including NxStage operations
  • 4 Before special items
  • 5 Before special items, including IFRS 16, including NxStage operations
  • 6 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
  •  
  • As of December 31, 2019

 

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com


Contacts
Visit us

Fresenius SE & Co. KGaA

We use cookies to create cross-page statistical evaluations that we use to tailor our web pages to meet your needs. By clicking on "Yes", you agree to the use of these cookies. You will find more detailed information about these cookies and the associated data processing as well as the possibility of revocation in our data protection policy. To select individual types of cookies, please use the cookie settings.

Learn more
Yes No